Cargando…

Trastuzumab/pertuzumab combination therapy stimulates antitumor responses through complement-dependent cytotoxicity and phagocytosis

Two HER2-specific mAbs, trastuzumab and pertuzumab (T+P), combined with chemotherapy comprise standard-of-care treatment for advanced HER2(+) breast cancers (BC). While this antibody combination is highly effective, its synergistic mechanism-of-action (MOA) remains incompletely understood. Past stud...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tsao, Li-Chung, Crosby, Erika J., Trotter, Timothy N., Wei, Junping, Wang, Tao, Yang, Xiao, Summers, Amanda N., Lei, Gangjun, Rabiola, Christopher A., Chodosh, Lewis A., Muller, William J., Lyerly, Herbert Kim, Hartman, Zachary C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society for Clinical Investigation 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8986081/ https://www.ncbi.nlm.nih.gov/pubmed/35167491 http://dx.doi.org/10.1172/jci.insight.155636

Ejemplares similares

Biomarker analysis of the NeoSphere study: pertuzumab, trastuzumab, and docetaxel versus trastuzumab plus docetaxel, pertuzumab plus trastuzumab, or pertuzumab plus docetaxel for the neoadjuvant treatment of HER2-positive breast cancer
por: Bianchini, Giampaolo, et al.
Publicado: (2017)

Characterization of infections and hypogammaglobulinemia treated with the combination of pertuzumab and trastuzumab
por: Mortimer, Joanne E., et al.
Publicado: (2019)

The combination of trastuzumab and pertuzumab administered at approved doses may delay development of trastuzumab resistance by additively enhancing antibody-dependent cell-mediated cytotoxicity
por: Tóth, Gábor, et al.
Publicado: (2016)

Sensitizing immune unresponsive colorectal cancers to immune checkpoint inhibitors through MAVS overexpression
por: Hwang, Bin-Jin, et al.
Publicado: (2022)

In vitro activity of pertuzumab in combination with trastuzumab in uterine serous papillary adenocarcinoma
por: El-Sahwi, K, et al.
Publicado: (2010)

Skin/nail infections with the addition of pertuzumab to trastuzumab-based chemotherapy
por: Mortimer, Joanne, et al.
Publicado: (2014)

Cryo-EM Structure of HER2-trastuzumab-pertuzumab complex
por: Hao, Yue, et al.
Publicado: (2019)

BERENICE Final Analysis: Cardiac Safety Study of Neoadjuvant Pertuzumab, Trastuzumab, and Chemotherapy Followed by Adjuvant Pertuzumab and Trastuzumab in HER2-Positive Early Breast Cancer
por: Dang, Chau, et al.
Publicado: (2022)

Pertuzumab Increases 17-AAG-Induced Degradation of ErbB2, and This Effect Is Further Increased by Combining Pertuzumab with Trastuzumab
por: Hughes, Juliana Bentes, et al.
Publicado: (2012)

Defining the molecular response to trastuzumab, pertuzumab and combination therapy in ovarian cancer
por: Sims, A H, et al.
Publicado: (2012)

The Effects of Pertuzumab and Its Combination with Trastuzumab on HER2 Homodimerization and Phosphorylation
por: Nami, Babak, et al.
Publicado: (2019)

Correction: Cryo-EM Structure of HER2-trastuzumab-pertuzumab complex
por: Hao, Yue, et al.
Publicado: (2019)

Trastuzumab Associated With Recurrent Severe Thrombocytopenia and Successful Use of Pertuzumab Monotherapy
por: Huff, Mallorie L, et al.
Publicado: (2022)

Pruritus Related to Trastuzumab and Pertuzumab in HER2+ Breast Cancer Patients
por: Gu, Stephanie, et al.
Publicado: (2023)

MOGAD patient autoantibodies induce complement, phagocytosis, and cellular cytotoxicity
por: Yandamuri, Soumya S., et al.
Publicado: (2023)

Neratinib plus trastuzumab is superior to pertuzumab plus trastuzumab in HER2-positive breast cancer xenograft models
por: Veeraraghavan, Jamunarani, et al.
Publicado: (2021)

Neoadjuvant T-DM1/pertuzumab and paclitaxel/trastuzumab/pertuzumab for HER2(+) breast cancer in the adaptively randomized I-SPY2 trial
por: Clark, Amy S., et al.
Publicado: (2021)

Binding Affinity of Trastuzumab and Pertuzumab Monoclonal Antibodies to Extracellular HER2 Domain †
por: Cruz, Victor L., et al.
Publicado: (2023)

Combination efficacy of pertuzumab and trastuzumab for trastuzumab emtansine-resistant cells exhibiting attenuated lysosomal trafficking or efflux pumps upregulation
por: Yamashita-Kashima, Yoriko, et al.
Publicado: (2020)

Comparative Effectiveness and Safety of Pertuzumab and Trastuzumab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy for Treatment of Metastatic Breast Cancer
por: Dai, Wei Fang, et al.
Publicado: (2022)

Enrichment and Liquid Chromatography–Mass Spectrometry Analysis of Trastuzumab and Pertuzumab Using Affimer Reagents
por: Olaleye, Oladapo, et al.
Publicado: (2021)

Ovarian cancer with high-level focal ERBB2 amplification responds to trastuzumab and pertuzumab
por: Thouvenin, Laure, et al.
Publicado: (2021)

Pertuzumab in Combination with Trastuzumab and Docetaxel in the Neoadjuvant Treatment for HER2-Positive Breast Cancer
por: Vieira, Cláudia, et al.
Publicado: (2022)

HER2-LAMP vaccines effectively traffic to endolysosomal compartments and generate enhanced polyfunctional T cell responses that induce complete tumor regression
por: Chen, Alan Chen, et al.
Publicado: (2020)

Polyfunctional anti-human epidermal growth factor receptor 3 (anti-HER3) antibodies induced by HER3 vaccines have multiple mechanisms of antitumor activity against therapy resistant and triple negative breast cancers
por: Osada, Takuya, et al.
Publicado: (2018)

Mechanisms Underlying the Action and Synergism of Trastuzumab and Pertuzumab in Targeting HER2-Positive Breast Cancer
por: Nami, Babak, et al.
Publicado: (2018)

A search for synergy in the binding kinetics of Trastuzumab and Pertuzumab whole and F(ab) to Her2
por: Lua, Wai-Heng, et al.
Publicado: (2015)

Tumor lysis syndrome following trastuzumab and pertuzumab for metastatic breast cancer: a case report
por: Baudon, C., et al.
Publicado: (2016)

Development and validation of an LC-MS/MS method for simultaneous quantification of co-administered trastuzumab and pertuzumab
por: Schokker, Sandor, et al.
Publicado: (2020)

Association of Pertuzumab, Trastuzumab, and Docetaxel Combination Therapy With Overall Survival in Patients With Metastatic Breast Cancer
por: Ramagopalan, Sreeram V., et al.
Publicado: (2021)

Cardiotoxicity after Additional Administration of Pertuzumab following Long-Term Trastuzumab: Report of 2 Cases
por: Ito, Mayuko, et al.
Publicado: (2021)

Trastuzumab Emtansine Plus Pertuzumab Versus Taxane Plus Trastuzumab Plus Pertuzumab After Anthracycline for High-Risk Human Epidermal Growth Factor Receptor 2–Positive Early Breast Cancer: The Phase III KAITLIN Study
por: Krop, Ian E., et al.
Publicado: (2022)

Cancer vaccines: the importance of targeting oncogenic drivers and the utility of combinations with immune checkpoint inhibitors
por: Crosby, Erika J., et al.
Publicado: (2021)

Beyond Neoantigens: Antigens Derived from Tumor Drivers as Cancer Vaccine Targets
por: Crosby, Erika J., et al.
Publicado: (2023)

Cardiac Safety of Paclitaxel Plus Trastuzumab and Pertuzumab in Patients With HER2-Positive Metastatic Breast Cancer
por: Yu, Anthony F., et al.
Publicado: (2016)

Trastuzumab and pertuzumab in circulating tumor DNA ERBB2-amplified HER2-positive refractory cholangiocarcinoma
por: Yarlagadda, Bhavya, et al.
Publicado: (2019)

Clinical efficacy of combination of pertuzumab, trastuzumab, and docetaxel for treatment of patients with HER2-positive breast cancer
por: Liu, Yan-cui, et al.
Publicado: (2019)

Not all therapeutic antibody isotypes are equal: the case of IgM versus IgG in Pertuzumab and Trastuzumab
por: Samsudin, Firdaus, et al.
Publicado: (2020)

Ado-trastuzumab for the treatment of metastatic HER2-positive breast cancer in patients previously treated with Pertuzumab
por: Al Rabadi, Luai S., et al.
Publicado: (2021)

Pertuzumab and Trastuzumab Combination with Concomitant Locoregional Radiotherapy for the Treatment of Breast Cancers with HER2 Receptor Overexpression
por: Aboudaram, Amélie, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_2ilbeureo4sfb1ou4cftobd3bi